To examine if EphA3-targeting RIT could have benefit as a GBM therapy we radiolabelled IIIA4-DOTA with the β particle-emitting radionuclide lutetium-177 (177Lu-IIIA4). The gene discussed is EPHA3; the disease is glioblastoma.